Effect of everolimus on left ventricular hypertrophy of de novo kidney transplant recipients: A 1 year, randomized, controlled trial

Transplantation

Volumn 93, Issue 5, 2012, Pages 503-508

  Paoletti, Ernesto ^a   Marsano, Luigina ^a   Bellino, Diego ^a   Cassottana, Paolo ^a   Cannella, Giuseppe ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Calcineurin inhibitors; Everolimus; LVH; Renal transplantation

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; CYCLOSPORIN A; DIURETIC AGENT; EVEROLIMUS; HEMOGLOBIN; IMMUNOSUPPRESSIVE AGENT; LIPID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RENIN INHIBITOR; STEROID;

ACUTE GRAFT REJECTION; ADULT; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CARDIOVASCULAR PARAMETERS; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG EXPOSURE; ECHOCARDIOGRAPHY; FEMALE; GRAFT RECIPIENT; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HUMAN; HUMAN TISSUE; INTERVENTRICULAR SEPTUM THICKNESS; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; LEFT VENTRICULAR POSTERIOR WALL THICKNESS; MALE; OPEN STUDY; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE;

ADULT; AGED; BIOLOGICAL MARKERS; BLOOD PRESSURE; CHI-SQUARE DISTRIBUTION; CYCLOSPORINE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; IMMUNOSUPPRESSIVE AGENTS; ITALY; KIDNEY TRANSPLANTATION; LINEAR MODELS; MALE; MIDDLE AGED; RISK ASSESSMENT; RISK FACTORS; SIROLIMUS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84857515891     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e318242be28     Document Type: Article

References (28)

1. Rigatto C, Foley RN, Jeffery J, et al. Electrocardiographic left ventricular hypertrophy in renal transplant recipients: Prognostic value and impact of blood pressure and anemia. J Am Soc Nephrol 2003;14:462.
2. Paoletti E, Amidone M, Cassottana P, et al. Effect of sirolimus on left ventricular hypertrophy in kidney transplant recipients: A 1-year nonrandomized controlled trial. Am J Kidney Dis 2008;52:324.
3. Raichlin E, Chandrasekaran K, Kremers WK, et al. Sirolimus as primary immunosuppressant reduces left ventricular mass and improves diastolic function of the cardiac allograft. Transplantation 2008;86:1395.
4. Cravedi P, Ruggenenti P, Remuzzi G. Sirolimus for calcineurin inhibitors in organ transplantation: Contra. Kidney Int 2010;78:1068.
5. Schuler W, Sedrani R, Cottens S, et al. SDZ RAD, a new, rapamycin derivative: Pharmacological properties in vitro and in vivo. Transplantation 1997;64:36.
6. Tedesco-Silva H Jr, Vitko S, Pascual J, et al. 12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients. Transpl Int 2007;20:27.
7. Shioi T, McMullen JR, Tarnavski O, et al. Rapamycin attenuates loadinduced cardiac hypertrophy in mice. Circulation 2003;107:1664.
8. McMullen JR, Sherwood MC, Tarnavski O, et al. Inhibition of mTOR signaling with rapamycin regresses established cardiac hypertrophy induced by pressure overload. Circulation 2004;109:3050.
9. Siedlecki AM, Jin X, Muslin AJ. Uremic cardiac hypertrophy is reversed by rapamycin but not by lowering of blood pressure. Kidney Int 2009;75:800.
10. Gao XM, Wong G, Wang B, et al. Inhibition of mTOR reduces chronic pressure-overload cardiac hypertrophy and fibrosis. J Hypertension 2006;24:1663.
11. Mall G, Huther W, Schneider J, et al. Diffuse intercardiomyocytic fibrosis in uraemic patients. Nephrol Dial Transplant 1990;5:39.
12. Mark PB, Johnston N, Groenning BA, et al. Redefinition of uremic cardiomyopathy by contrast-enhanced cardiac magnetic resonance imaging. Kidney Int 2006;69:1839.
13. Salvetti M, Muiesan ML, Paini A, et al. Myocardial ultrasound tissue characterization in patients with chronic renal failure. J AmSoc Nephrol 2007;18:1953.
14. Salvadori M, Scolari MP, Bertoni E, et al. Everolimus with very lowexposure cyclosporine A in de novo kidney transplantation: A multicenter, randomized, controlled trial. Transplantation 2009;88:1194.
15. Tedesco-Silva H Jr, Cibrik D, Johnston T, et al. Everolimus plus reducedexposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant patients. Am J Transplant 2010;10:1401.
16. Johnston O, Rose CL, Webster AC, et al. Sirolimus is associated with new-onset diabetes in kidney transplant recipients. J Am Soc Nephrol 2008;19:1411.
17. Halimi JM, Buchler M, Al Najjar A, et al. Urinary albumin excretion and the risk of graft loss and death in proteinuric and non-proteinuric renal transplant recipients. Am J Transplant 2007;7:618.
18. Vitko S, Tedesco H, Eris J, et al. Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies. Am J Transplant 2004;4:626.
19. Chan L, Greenstein S, Hardy MA, et al. Multicenter, randomized study of the use of everolimus with tacrolimus after renal transplantation demonstrates its effectiveness. Transplantation 2008;85:821.
20. Hernandez D, Lacalzada J, Salido E, et al. Regression of left ventricular hypertrophy by lisinopril after renal transplantation: Role of ACE gene polymorphism. Kidney Int 2000;58:889.
21. Paoletti E, Cassottana P, Amidone M, et al. ACE inhibitors and persistent left ventricular hypertrophy after renal transplantation: A randomized clinical trial. Am J Kidney Dis 2007;50:133.
22. Zhang D, Contu R, Latronico M V G, et al. MTORC1 regulates cardiac function and myocyte survival through 4E-BP1 inhibition in mice. J Clin Invest 2010;120:2805.
23. Lentine KL, Schnitzler MA, Abbott KC, et al. De novo congestive heart failure after kidney transplantation: A common condition with poor prognostic implications. Am J Kidney Dis 2005;46:720.
24. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007;357:2562.
25. K/DOQI Clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004;43(suppl 1): S1.
26. Sahn DJ, De Maria A, Kisslo J, et al. Recommendations regarding quantitation in M-mode echocardiography: Results of a survey of echocardiographic measurements. Circulation 1978;58:1072.
27. Devereux RB, Alonso DR, Lutas EM, et al. Echocardiographic assessment of left ventricular hypertrophy: Comparison to necroscopy findings. Am J Cardiol 1986;57:450.
28. Ferrara LA, Vaccaro O, Cardoni O, et al. Indexation criteria of left ventricular mass and predictive role of blood pressure and body composition. Am J Hypertens 2005;18:1263.